title: Anti-HIV potential of a new interferon, interferon-tau (trophoblastin).
abstract: Antiretroviral effects of a new class of interferon (IFN), IFN-tau, were compared with those of IFN-alpha in primary peripheral blood lymphocytes (PBLs) and monocyte-derived macrophages (MDMs), infected in vitro by human immunodeficiency viruses type 1, HIV-1/LAI, and HIV-1/DAS isolates, respectively. Cells were treated with recombinant IFN 24 h before or after HIV infection and then continuously exposed. Viral replication was monitored twice a week by quantifying the reverse transcriptase activity in cell culture supernatants. Integrated proviral DNA was monitored 24 h after infection in IFN-tau-pretreated MDMs, using specific gag gene amplification by the polymerase chain reaction. IFN-tau inhibited HIV-1 replication in both PBLs and MDMs as well as in peripheral blood mononuclear cells (PBMCs). IFN-tau was 35-fold more potent than IFN-alpha in PBLs and 100-fold more potent in MDMs. Differences were observed in the amount of integrated proviral DNA between untreated and 10 IU/ml IFN-tau-treated HIV-infected MDMs. IFN-tau exhibits significant anti-HIV activity in comparison to IFN-alpha, and like other IFNs, it seems to interact with several steps of HIV replication cycle.
authors.affiliation: Service de Neurovirologie, Commissariat à l'Energie Atomique, Institut Paris Sud sur les Cytokines, Fontenay aux Roses, France.
authors.forename: N
authors.initials: N
authors.lastname: Dereuddre-Bosquet
authors.forename: P
authors.initials: P
authors.lastname: Clayette
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Mabondzo
authors.forename: P
authors.initials: P
authors.lastname: Frétier
authors.forename: G
authors.initials: G
authors.lastname: Gras
authors.forename: J
authors.initials: J
authors.lastname: Martal
authors.forename: D
authors.initials: D
authors.lastname: Dormont
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000302:isolation & purification; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D016898:Interferon-alpha / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000821:virology; D008264:Macrophages / Q000821:virology; D011257:Pregnancy Proteins / Q000494:pharmacology*; D011533:Proviruses / Q000302:isolation & purification; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D007370:Interferon Type I; D016898:Interferon-alpha; D011257:Pregnancy Proteins; C020947:interferon tau